시장보고서
상품코드
1309703

세계의 인슐린 펌프 시장 규모, 점유율, 산업 동향 분석 보고서 : 제품별, 적응 질환별, 유통 채널별(소매점, 온라인 약국, 병원 약국), 지역별 전망과 예측(2023-2030년)

Global Insulin Pump Market Size, Share & Industry Trends Analysis Report By Product, By Disease Indication, By Distribution Channel (Retail & Online Pharmacies, and Hospital Pharmacy), By Regional Outlook and Forecast, 2023 - 2030

발행일: | 리서치사: KBV Research | 페이지 정보: 영문 224 Pages | 배송안내 : 즉시배송


※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 인슐린 펌프(Insulin Pump) 시장 규모는 2030년 95억 달러 규모에 달할 것으로 예측되며, 예측 기간 중 9.9%의 CAGR 규모로 성장하여 상승할 전망입니다.

KBV Cardinal 매트릭스에 제시된 분석에 따르면 F. Hoffmann-La Roche Ltd.는 시장 최고 기업입니다. 2021년 1월 F. Hofman La Roche는 캐나다 고객에게 SiteSmart 펜형 주사 바늘 시스템을 제공하기 위해 Montmed Inc.와 파트너십을 체결했습니다. 이 제휴는 당뇨병 관리를 개선하는 로슈 목표를 지원합니다. Medtronic PLC, Aetna, Inc., Insulet Corporation 등의 기업이 시장 주요 혁신자입니다.

COVID-19 영향

COVID-19 발생은 인슐린 펌프 시장 확대를 막았습니다. 당뇨병 진단과 치료 지연, 환자 펌프 구입 지연이 일어나고 있습니다. 또한 COVID-19 대유행 시에는 일부 정부가 규제를 마련하였으며 펌프와 소모품 공급이 중단되었습니다. 예를 들어 미국 당뇨병 협회 보고에 따르면, 유행기간 동안 펌프나 CGM을 사용하는 당뇨병 환자 15%가 소모품 보충을 지연시켰습니다. 질병 인식과 진단이 증가함에 따라 CGM과 폐쇄 루프 펌프 매출은 2021년 20% 증가할 전망입니다. 시장 진출기업의 수익 마진은 2020년 크게 감소했습니다.

시장 성장 요인

세계의 당뇨병 이환율 증가

선진국이든 신흥국이든 당뇨병은 더욱 흔해지고 있습니다. 이것은 비만과 앉을 수 없는 라이프 스타일과 같은 몇 가지 요소의 결과입니다. 당뇨병에 관한 사실과 수치는 세계의 사람들, 가족, 국가들에게 당뇨병이 얼마나 어려운지를 보여줍니다. IDF 당뇨병 아틀라스(2021년)에 따르면 성인(20-79세) 10.5%가 당뇨병이고, 절반 가까이 자신이 당뇨병임을 전혀 모릅니다. IDF 예측에 따르면 2045년 성인 8명 중 1명에 해당하는 7억 8,300만명이 당뇨병을 앓게 되어 46% 증가합니다. 제2형 당뇨병은 사회경제적, 인구통계적, 환경적, 유전적 변수에 의해 발생하며, 당뇨병 환자의 90% 이상이 영향을 받습니다. 당뇨병 환자는 이러한 펌프와 질병 관리 장점을 더 잘 인식하기 때문에 시장이 상승할 것으로 예상됩니다.

제품 출시 및 승인 증가

신흥국 당뇨병 환자 보급이 진행됨에 따라 시장 진출기업은 기술적으로 개선된 제품 연구개발에 주력하고 시장에 신상품을 투입할 필요가 있습니다. 이러한 연구개발 이니셔티브는 MDI 요법을 받은 2형 당뇨병 환자와는 대조적으로 펌프 요법을 받은 2형 당뇨병 환자 포도당 조절 지속적인 개선을 입증하는 수많은 임상 연구에 의해 지원되었습니다. 그 결과, 시장은 향후 수년간 성장할 것으로 예상됩니다.

시장 성장 억제 요인

인슐린 펌프는 일반적으로 고가

예상되는 기간 동안, 시장 성장은 인슐린 펌프의 높은 비용에 의해 억제될 것으로 예상됩니다. 기존 헬스케어 원동력은 이러한 최신 약물전달 시스템에 의해 근저로부터 덮여 있어 헬스케어 분야에도 변화를 가져오고 있습니다. 예를 들어 미국 당뇨병 협회가 2019년 4월에 실시한 조사에 따르면 당뇨병 환자 인슐린 펌프 요법은 MDI 요법보다 고액이며, 그 가격차는 약 43.5%였습니다. 또한 이러한 펌프 자기 부담액이 큰 것은 환자 펌프 사용 의욕을 깎고 있습니다.

제품 전망

제품별 시장은 펌프와 소모품으로 나뉘며 2022년 펌프 부문시장 가장 큰 판매 점유율을 차지했습니다. 이 부문 확장은 선진국 당뇨병 환자 펌프 사용 증가로 인한 전망입니다. 여러 지속 포도당 모니터 매일 주사 및 기타 기술에 비해 이러한 제품은 몇 가지 장점을 제공합니다. Tandem사 간부에 따르면, 1형 당뇨병 환자 펌프 채용은 국내 시장과 국제 시장 모두 견인력이 증가함에 따라 확대될 전망입니다.

펌프 유형 전망

펌프 유형별로 시장은 패치, 테더 등으로 나뉩니다. 2022년 시장은 테더형이 가장 높은 수익 점유율을 차지하고 있습니다. 이 부문의 시장 규모가 큰 것은 주로 클래식 펌프의 신뢰성과 폭넓은 제품 라인업 덕분입니다. 포켓에 넣어 운반할 수 있는 휴대성과 편리성에 의해 테더 펌프 인기가 높아지고 있습니다. 또한 모바일 장치를 사용하여 혈당을 쉽게 제어하고 모니터링할 수 있습니다. 이러한 장점으로 테더 펌프 수요가 증가하고 있습니다.

적응 질환별 전망

당뇨병 적응증별로 시장은 1형 당뇨병과 2형 당뇨병으로 세분화되며 2형 당뇨병 부문이 2022년 시장 큰 수익 점유율을 얻었습니다. 이 질환 유병률이 세계적으로 상승하고 있기 때문에 2형 당뇨병 부문은 예측 기간 동안 서서히 성장할 것으로 예측됩니다. 시장 확대는 인슐린 의존형 2형 당뇨병 환자 수 증가와 환자가 MDI 펌프나 다른 대체 치료법으로 전환함으로써 조장될 전망입니다.

유통 채널 전망

유통 채널별로는 시장은 소매 및 온라인 약국과 병원 약국으로 나뉘며 2022년 소매 및 온라인 약국 부문이 시장에서 가장 높은 판매 점유율을 차지했습니다. 선진국 및 신흥국 소매점과 의약품 판매점는 당뇨병 관리 기기와 솔루션을 보다 용이하게 입수할 수 있었기에 시장 상당 부분을 차지하는 소매점, 온라인 약국 부문이 시장을 견인했습니다. 인터넷 이용 확대도 이 틈새 분야 시장 확대에 기여하고 있습니다.

지역별 전망

지역별로 시장은 북미, 유럽, 아시아태평양, LAMEA로 구분됩니다. 2022년 북미가 가장 높은 수익 점유율을 획득하여 시장을 선도했습니다. 이는 이 지역 여러 주요 시장 진출 기업, 당뇨병 유병률 상승, 새로운 약물 전달 기술의 사회적 수요 증가가 기여하고 있습니다. 인슐린 펌프 보급은 가처분 소득 증가와 건강 의식 증가에 의해 촉진되고 있으며, 이 지역은 예측 기간 동안에도 주도권을 유지할 것으로 보입니다.

목차

제1장 시장 범위와 조사 방법

  • 시장 정의
  • 목적
  • 시장 범위
  • 세분화
  • 조사 방법

제2장 시장 주요 요약

  • 소개
    • 주요 요약
      • 시장 구성과 시나리오
  • 시장에 영향을 미치는 주요 요인
    • 시장 성장 촉진 요인
    • 시장 성장 억제 요인

제3장 경쟁 분석

  • KBV Cardinal Matrix
  • 최근 업계 전체 전략 전개
    • 파트너십, 협업 및 계약
    • 제품 출시 및 제품 확대
    • 인수와 합병
    • 시험 및 승인
    • 지리적 확대
  • 주요 성공 전략
    • 주요 전략
    • 주요 전략 움직임

제4장 세계의 인슐린 펌프 시장 : 제품별

  • 세계의 펌프 시장 : 지역별
  • 세계의 인슐린 펌프 시장 : 펌프 유형별
    • 세계의 테더 시장 : 지역별
    • 세계의 패치 시장 : 지역별
    • 세계의 기타 시장 : 지역별
  • 세계의 소모품 시장 : 지역별

제5장 세계의 인슐린 펌프 시장 : 질환 적응증별

  • 세계의 1형 당뇨병 시장 : 지역별
  • 세계의 2형 당뇨병 시장 : 지역별

제6장 세계의 인슐린 펌프 시장 : 유통 채널별

  • 세계의 소매 및 온라인 약국 시장 : 지역별
  • 세계의 병원 약국 시장 : 지역별

제7장 세계의 인슐린 펌프 시장 : 지역별

  • 북미
    • 북미 시장 : 국가별
      • 미국
      • 캐나다
      • 멕시코
      • 기타 북미
  • 유럽
    • 유럽 시장 : 국가별
      • 독일
      • 영국
      • 프랑스
      • 러시아
      • 스페인
      • 이탈리아
      • 기타 유럽
  • 아시아태평양
    • 아시아태평양 시장 : 국가별
      • 중국
      • 일본
      • 인도
      • 한국
      • 싱가포르
      • 말레이시아
      • 기타 아시아태평양
  • 라틴아메리카, 중동, 아프리카
    • 라틴아메리카, 중동, 아프리카 시장 : 국가별
      • 브라질
      • 아르헨티나
      • 아랍에미리트(UAE)
      • 사우디아라비아
      • 남아프리카
      • 나이지리아
      • 기타 라틴아메리카, 중동, 아프리카

제8장 기업 프로필

  • Tandem Diabetes Care, Inc
  • SOOIL Developments Co, Ltd
  • Jiangsu Delfu Medical Device Co,Ltd
  • Medtronic PLC
  • F Hoffmann-La Roche Ltd.
  • Insulet Corporation
  • Ypsomed AG
  • Aetna, Inc(CVS Pharmacy, Inc.)
  • Diabeloop SA
  • APEX Medical Corporation
NJH 23.08.24

The Global Insulin Pump Market size is expected to reach $9.5 billion by 2030, rising at a market growth of 9.9% CAGR during the forecast period.

Asia-Pacific region widely utilizes Insulin Pumps as a sizable portion of the world's population resides in Asia Pacific, and the region's consumers are changing their eating habits, leading to an increase in the number of diabetics. Hence, Asia Pacific captured $1,090.5 million revenue in the market in 2022. Additionally, it is anticipated that in the near future, rising consumer healthcare spending, increased retail pharmacy penetration, and rising health awareness in the region will fuel the expansion of the market in Asia Pacific.

The major strategies followed by the market participants are Partnerships as the key developmental strategy to keep pace with the changing demands of end users. For instance, In March, 2023, Diabeloop SA entered into a partnership with Novo Nordisk to integrate its 4penTM with Novo Nordisk's reusable and connected insulin pens. The integration of the two offerings would bring better-automated solutions to diabetic patients. Additionally, In June, 2022, SOOIL Developments Co., Ltd partnered with Diabeloop, to integrate their offerings. The interoperability between the offerings would provide customers with better diabetes management solutions.

Based on the Analysis presented in the KBV Cardinal matrix; F. Hoffmann-La Roche Ltd. is the forerunner in the Market. In January, 2021, F. Hoffmann-La Roche Ltd. entered into a partnership with Montmed Inc. to provide a SiteSmart pen needle system to Canadian customers. The partnership aids Roche in its goal of improving diabetes management. Companies such as Medtronic PLC, Aetna, Inc., Insulet Corporation are some of the key innovators in the Market.

COVID-19 Impact

The COVID-19 outbreak hindered the market expansion for insulin pumps. Delays in diabetes diagnosis and treatment, as well as in patients' purchases of these pumps at this time, were contributing factors. Additionally, during the COVID-19 pandemic, restrictions put in place by several governments resulted in interruptions in the delivery of pumps and supplies. For example, the American Diabetes Association reports that 15% of diabetics who use pumps or CGMs delayed replenishing their supplies during the pandemic. Due to rising disease awareness & diagnosis, CGM and closed-loop pump sales showed a 20% increase in 2021. The revenue margins of the market participants significantly decreased in 2020.

Market Growth Factors

Growing incidence of diabetes globally

Both in developed and emerging nations, diabetes is becoming more common. This is a result of several elements, such as obesity and a sedentary lifestyle. Facts and numbers on diabetes indicate how much of a hardship it is for people, families, and nations worldwide. 10.5% of adults (20-79 years) have diabetes, according to the IDF Diabetes Atlas (2021), and nearly half are completely ignorant that they have the disease. According to IDF predictions, 783 million adults, or one in eight, would have diabetes by 2045, a 46% rise. Type 2 diabetes, caused by socioeconomic, demographic, environmental, and hereditary variables, affects more than 90% of diabetics. During the forecast period, the market is expected to rise due to diabetic patients being more aware of these pumps and the advantages of disease management.

Rising product launches and approvals

The market players are urged to focus on research and development of technologically improved products and introduce new items to the market as the penetration of these pumps among diabetics in emerging nations rises. These R&D initiatives have been supported by numerous clinical studies that demonstrate sustained improvement in glucose control in type 2 diabetic individuals receiving pump therapy as opposed to those receiving MDI therapy. As a result, the market is predicted to grow in the upcoming years.

Market Restraining Factors

Insulin pumps are generally expensive

During the anticipated term, market growth is expected to be constrained by the high cost of insulin pumps. The dynamics of conventional healthcare have been upended by these contemporary drug delivery systems, which have also changed the healthcare sector. For instance, a study conducted by the American Diabetes Association in April 2019 found that insulin pump therapy for diabetic patients is more expensive than MDI therapy, with a price difference of about 43.5%. Also, the greater out-of-pocket costs related to these pumps have discouraged patients from using them.

Product Outlook

On the basis of product, the market is bifurcated into pumps and consumables. In 2022, the pumps segment witnessed the largest revenue share in the market. The segment's expansion results from the diabetic population's rising use of them in industrialized nations. Compared to several continuous glucose monitors, daily injections, and other technologies, these goods provide several advantages. The adoption of pumps among patients with type 1 diabetes is expected to grow as they gain traction in both the domestic and international markets, according to senior Tandem executives.

Pumps Type Outlook

By pumps type, the market is divided into patch, tethered and others. The tethered held the highest revenue share in the market in 2022. The segment's significant market size is primarily attributable to the classic pumps' dependability and the wide range of products available. Due to their portability and convenience, that allow people to carry them in their pockets, tethered insulin pumps have grown in popularity. It may also be easily controlled and used to monitor blood glucose levels via mobile devices. These benefits have led to a rise in the demand for tethered pumps.

Disease Indication Outlook

By diabetes indication, the market is fragmented into Type 1 Diabetes, and Type 2 Diabetes. The Type 2 Diabetes segment garnered a significant revenue share in the market in 2022. Due to the rising prevalence of this condition worldwide, it is also anticipated that the type 2 diabetes segment will grow gradually throughout the course of the projected period. The market's expansion will also be aided by the rising number of type 2 diabetics who are insulin-dependent and by the patients switching from MDIs to pumps and another alternative treatment alternative.

Distribution Channel Outlook

By distribution channel, the market is bifurcated into retail & online pharmacy and hospital pharmacy. In 2022 the retail & online pharmacy segment held the highest revenue share in the market. The retail & online pharmacy segment, which had a sizable portion of the market, led because diabetic management devices &solutions were more readily available in retail & pharmaceutical outlets in developed and developing countries. The growing use of the internet also contributes to the market expansion in this niche.

Regional Outlook

Region wise, the market is analysed across North America, Europe, Asia-Pacific, and LAMEA. In 2022, the North America region led the market by generating the highest revenue share. This is aided by multiple major market participants in the region, higher diabetes prevalence, and rising public demand for novel medication delivery technologies. The population's adoption of insulin pumps has been prompted by rising disposable income and health awareness, and the region is expected to maintain its leadership during the forecast period.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Medtronic PLC, F. Hoffmann-La Roche Ltd., Tandem Diabetes Care, Inc., Insulet Corporation, Ypsomed AG, Aetna, Inc. (CVS Pharmacy, Inc.), SOOIL Developments Co., Ltd, Diabeloop SA, Jiangsu Delfu Medical Device Co.,Ltd, and APEX Medical Corporation

Recent Strategies Deployed in Insulin Pump Market

Partnerships, Collaborations, and Agreements:

2023-Mar: Diabeloop SA entered into a partnership with Novo Nordisk, a Danish healthcare company, to integrate its 4penTM with Novo Nordisk's reusable and connected insulin pens. The integration of the two offerings would bring better-automated solutions to diabetic patients.

2022-Nov: Ypsomed AG teamed up with CamDiab, a glucose level management solutions provider, to launch an automated insulin dosing system. The collaboration features the integration of Ypsomed's offerings with CamDiab's adaptive hybrid closed-loop app that would allow Ypsomed to better serve its diabetic patients.

2022-Jun: SOOIL Developments Co., Ltd partnered with Diabeloop, a diabetes management solutions provider, to integrate their offerings. The interoperability between the offerings would provide customers with better diabetes management solutions.

2021-Nov: Diabeloop SA announced a partnership with Terumo Corporation, a medical technology company, to develop solutions for Automated Insulin Delivery. The partnership enhances Diabeloop's position in the European market and would provide its customers with better diabetes care solutions.

2021-Jan: F. Hoffmann-La Roche Ltd. entered into a partnership with Montmed Inc., an Insulin delivery specialist based in Canada, to provide a SiteSmart pen needle system to Canadian customers. The partnership aids Roche in its goal of improving diabetes management.

Mergers & Acquisition:

2023-May: Medtronic PLC acquired EOFlow Co. Ltd., an insulin delivery solutions provider. The acquisition strengthens Medtronic's diabetes management portfolio.

2023-Feb: Insulet Corporation took over the automated insulin delivery assets of Automated Glucose Control LLC, an automated insulin delivery solution provider based in the United States. The acquisition would strengthen the company's ability to deliver automated insulin delivery technology.

2023-Feb: Insulet Corporation announced the acquisition of automated insulin delivery assets of Bigfoot Biomedical, an intelligent injection solutions provider. The acquisition enhances Insulet's IP portfolio.

2023-Jan; Tandem Diabetic Care, Inc. completed the acquisition of AMF Medical SA, an Insulin patch pump manufacturer. The acquisition would enhance the diabetes management expertise of the company by adding a well-experienced team.

Trials and Approvals:

2023-Apr: Medtronic PLC announced the approval by U.S. Food and Drug Administration (FDA) for its MiniMed 780G. The MiniMed 780G is an insulin injector system used when the consumer puts low carbs in their meal.

2023-Apr: The US FDA announced the approval for Insulet Corporation's Omnipod GO, an insulin delivery device used for the treatment of type 2 diabetes.

2022-Feb: Tandem Diabetes Care, Inc. received approval from U.S. Food and Drug Administration for its t:slim X2 insulin pump. The t:slim X2 is used to monitor glucose levels in the patient's body. Additionally, the t:slim X2 can be used along with t:connect mobile app.

Product Launches and Product Expansions:

2022-Nov: Medtronic PLC released the Medtronic Extended infusion set. The infusion set has a wear time of 7 days and uses a tubing connector that would be used for insulin stability.

2021-Mar: Roche has announced the launch of the new Accu-Chek Instant system, a new "connected" blood glucose monitoring (BGM) system, which supports and enables Roche's approach of integrated Personalized Diabetes Management (iPDM). iPDM is a holistic, patient-centered therapeutic approach with the ultimate goal of personalizing diabetes management to streamline care and improve clinical outcomes. iPDM aims to strengthen the care process, facilitates communication between patients and their healthcare team, and integrates tools that visualize and analyze data.

Geographical Expansions:

2022-Jun: Insulet Corporation expanded its geographical footprint by opening a new manufacturing facility in Johor Bahru, Malaysia. The new facility would be used for manufacturing the company's Omnipod Insulin Management System.

Scope of the Study

Market Segments covered in the Report:

By Product

  • Pumps
    • Pumps
    • Consumables
  • Consumables

By Disease Indication

  • Type 1 Diabetes
  • Type 2 Diabetes

By Distribution Channel

  • Retail & Online Pharmacies
  • Hospital Pharmacy

By Geography

  • North America
    • US
    • Canada
    • Mexico
    • Rest of North America
  • Europe
    • Germany
    • UK
    • France
    • Russia
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Singapore
    • Malaysia
    • Rest of Asia Pacific
  • LAMEA
    • Brazil
    • Argentina
    • UAE
    • Saudi Arabia
    • South Africa
    • Nigeria
    • Rest of LAMEA

Companies Profiled

  • Medtronic PLC
  • F. Hoffmann-La Roche Ltd.
  • Tandem Diabetes Care, Inc.
  • Insulet Corporation
  • Ypsomed AG
  • Aetna, Inc. (CVS Pharmacy, Inc.)
  • SOOIL Developments Co., Ltd
  • Diabeloop SA
  • Jiangsu Delfu Medical Device Co.,Ltd
  • APEX Medical Corporation

Unique Offerings from KBV Research

  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free

Table of Contents

Chapter 1. Market Scope & Methodology

  • 1.1 Market Definition
  • 1.2 Objectives
  • 1.3 Market Scope
  • 1.4 Segmentation
    • 1.4.1 Global Insulin Pump Market, by Product
    • 1.4.2 Global Insulin Pump Market, by Disease Indication
    • 1.4.3 Global Insulin Pump Market, by Distribution Channel
    • 1.4.4 Global Insulin Pump Market, by Geography
  • 1.5 Methodology for the research

Chapter 2. Market Overview

  • 2.1 Introduction
    • 2.1.1 Overview
      • 2.1.1.1 Market Composition and Scenario
  • 2.2 Key Factors Impacting the Market
    • 2.2.1 Market Drivers
    • 2.2.2 Market Restraints

Chapter 3. Competition Analysis - Global

  • 3.1 KBV Cardinal Matrix
  • 3.2 Recent Industry Wide Strategic Developments
    • 3.2.1 Partnerships, Collaborations and Agreements
    • 3.2.2 Product Launches and Product Expansions
    • 3.2.3 Acquisition and Mergers
    • 3.2.4 Trials and Approvals
    • 3.2.5 Geographical Expansions
  • 3.3 Top Winning Strategies
    • 3.3.1 Key Leading Strategies: Percentage Distribution (2019-2023)
    • 3.3.2 Key Strategic Move: (Partnerships, Collaborations & Agreements: 2020, Feb - 2023, Mar) Leading Players

Chapter 4. Global Insulin Pump Market by Product

  • 4.1 Global Pumps Market by Region
  • 4.2 Global Insulin Pump Market by Pumps Type
    • 4.2.1 Global Tethered Market by Region
    • 4.2.2 Global Patch Market by Region
    • 4.2.3 Global Others Market by Region
  • 4.3 Global Consumables Market by Region

Chapter 5. Global Insulin Pump Market by Disease Indication

  • 5.1 Global Type 1 Diabetes Market by Region
  • 5.2 Global Type 2 Diabetes Market by Region

Chapter 6. Global Insulin Pump Market by Distribution Channel

  • 6.1 Global Retail & Online Pharmacies Market by Region
  • 6.2 Global Hospital Pharmacy Market by Region

Chapter 7. Global Insulin Pump Market by Region

  • 7.1 North America Insulin Pump Market
    • 7.1.1 North America Insulin Pump Market by Product
      • 7.1.1.1 North America Pumps Market by Country
      • 7.1.1.2 North America Insulin Pump Market by Pumps Type
        • 7.1.1.2.1 North America Tethered Market by Country
        • 7.1.1.2.2 North America Patch Market by Country
        • 7.1.1.2.3 North America Others Market by Country
      • 7.1.1.3 North America Consumables Market by Country
    • 7.1.2 North America Insulin Pump Market by Disease Indication
      • 7.1.2.1 North America Type 1 Diabetes Market by Country
      • 7.1.2.2 North America Type 2 Diabetes Market by Country
    • 7.1.3 North America Insulin Pump Market by Distribution Channel
      • 7.1.3.1 North America Retail & Online Pharmacies Market by Country
      • 7.1.3.2 North America Hospital Pharmacy Market by Country
    • 7.1.4 North America Insulin Pump Market by Country
      • 7.1.4.1 US Insulin Pump Market
        • 7.1.4.1.1 US Insulin Pump Market by Product
        • 7.1.4.1.2 US Insulin Pump Market by Disease Indication
        • 7.1.4.1.3 US Insulin Pump Market by Distribution Channel
      • 7.1.4.2 Canada Insulin Pump Market
        • 7.1.4.2.1 Canada Insulin Pump Market by Product
        • 7.1.4.2.2 Canada Insulin Pump Market by Disease Indication
        • 7.1.4.2.3 Canada Insulin Pump Market by Distribution Channel
      • 7.1.4.3 Mexico Insulin Pump Market
        • 7.1.4.3.1 Mexico Insulin Pump Market by Product
        • 7.1.4.3.2 Mexico Insulin Pump Market by Disease Indication
        • 7.1.4.3.3 Mexico Insulin Pump Market by Distribution Channel
      • 7.1.4.4 Rest of North America Insulin Pump Market
        • 7.1.4.4.1 Rest of North America Insulin Pump Market by Product
        • 7.1.4.4.2 Rest of North America Insulin Pump Market by Disease Indication
        • 7.1.4.4.3 Rest of North America Insulin Pump Market by Distribution Channel
  • 7.2 Europe Insulin Pump Market
    • 7.2.1 Europe Insulin Pump Market by Product
      • 7.2.1.1 Europe Pumps Market by Country
      • 7.2.1.2 Europe Insulin Pump Market by Pumps Type
        • 7.2.1.2.1 Europe Tethered Market by Country
        • 7.2.1.2.2 Europe Patch Market by Country
        • 7.2.1.2.3 Europe Others Market by Country
      • 7.2.1.3 Europe Consumables Market by Country
    • 7.2.2 Europe Insulin Pump Market by Disease Indication
      • 7.2.2.1 Europe Type 1 Diabetes Market by Country
      • 7.2.2.2 Europe Type 2 Diabetes Market by Country
    • 7.2.3 Europe Insulin Pump Market by Distribution Channel
      • 7.2.3.1 Europe Retail & Online Pharmacies Market by Country
      • 7.2.3.2 Europe Hospital Pharmacy Market by Country
    • 7.2.4 Europe Insulin Pump Market by Country
      • 7.2.4.1 Germany Insulin Pump Market
        • 7.2.4.1.1 Germany Insulin Pump Market by Product
        • 7.2.4.1.2 Germany Insulin Pump Market by Disease Indication
        • 7.2.4.1.3 Germany Insulin Pump Market by Distribution Channel
      • 7.2.4.2 UK Insulin Pump Market
        • 7.2.4.2.1 UK Insulin Pump Market by Product
        • 7.2.4.2.2 UK Insulin Pump Market by Disease Indication
        • 7.2.4.2.3 UK Insulin Pump Market by Distribution Channel
      • 7.2.4.3 France Insulin Pump Market
        • 7.2.4.3.1 France Insulin Pump Market by Product
        • 7.2.4.3.2 France Insulin Pump Market by Disease Indication
        • 7.2.4.3.3 France Insulin Pump Market by Distribution Channel
      • 7.2.4.4 Russia Insulin Pump Market
        • 7.2.4.4.1 Russia Insulin Pump Market by Product
        • 7.2.4.4.2 Russia Insulin Pump Market by Disease Indication
        • 7.2.4.4.3 Russia Insulin Pump Market by Distribution Channel
      • 7.2.4.5 Spain Insulin Pump Market
        • 7.2.4.5.1 Spain Insulin Pump Market by Product
        • 7.2.4.5.2 Spain Insulin Pump Market by Disease Indication
        • 7.2.4.5.3 Spain Insulin Pump Market by Distribution Channel
      • 7.2.4.6 Italy Insulin Pump Market
        • 7.2.4.6.1 Italy Insulin Pump Market by Product
        • 7.2.4.6.2 Italy Insulin Pump Market by Disease Indication
        • 7.2.4.6.3 Italy Insulin Pump Market by Distribution Channel
      • 7.2.4.7 Rest of Europe Insulin Pump Market
        • 7.2.4.7.1 Rest of Europe Insulin Pump Market by Product
        • 7.2.4.7.2 Rest of Europe Insulin Pump Market by Disease Indication
        • 7.2.4.7.3 Rest of Europe Insulin Pump Market by Distribution Channel
  • 7.3 Asia Pacific Insulin Pump Market
    • 7.3.1 Asia Pacific Insulin Pump Market by Product
      • 7.3.1.1 Asia Pacific Pumps Market by Country
      • 7.3.1.2 Asia Pacific Insulin Pump Market by Pumps Type
        • 7.3.1.2.1 Asia Pacific Tethered Market by Country
        • 7.3.1.2.2 Asia Pacific Patch Market by Country
        • 7.3.1.2.3 Asia Pacific Others Market by Country
      • 7.3.1.3 Asia Pacific Consumables Market by Country
    • 7.3.2 Asia Pacific Insulin Pump Market by Disease Indication
      • 7.3.2.1 Asia Pacific Type 1 Diabetes Market by Country
      • 7.3.2.2 Asia Pacific Type 2 Diabetes Market by Country
    • 7.3.3 Asia Pacific Insulin Pump Market by Distribution Channel
      • 7.3.3.1 Asia Pacific Retail & Online Pharmacies Market by Country
      • 7.3.3.2 Asia Pacific Hospital Pharmacy Market by Country
    • 7.3.4 Asia Pacific Insulin Pump Market by Country
      • 7.3.4.1 China Insulin Pump Market
        • 7.3.4.1.1 China Insulin Pump Market by Product
        • 7.3.4.1.2 China Insulin Pump Market by Disease Indication
        • 7.3.4.1.3 China Insulin Pump Market by Distribution Channel
      • 7.3.4.2 Japan Insulin Pump Market
        • 7.3.4.2.1 Japan Insulin Pump Market by Product
        • 7.3.4.2.2 Japan Insulin Pump Market by Disease Indication
        • 7.3.4.2.3 Japan Insulin Pump Market by Distribution Channel
      • 7.3.4.3 India Insulin Pump Market
        • 7.3.4.3.1 India Insulin Pump Market by Product
        • 7.3.4.3.2 India Insulin Pump Market by Disease Indication
        • 7.3.4.3.3 India Insulin Pump Market by Distribution Channel
      • 7.3.4.4 South Korea Insulin Pump Market
        • 7.3.4.4.1 South Korea Insulin Pump Market by Product
        • 7.3.4.4.2 South Korea Insulin Pump Market by Disease Indication
        • 7.3.4.4.3 South Korea Insulin Pump Market by Distribution Channel
      • 7.3.4.5 Singapore Insulin Pump Market
        • 7.3.4.5.1 Singapore Insulin Pump Market by Product
        • 7.3.4.5.2 Singapore Insulin Pump Market by Disease Indication
        • 7.3.4.5.3 Singapore Insulin Pump Market by Distribution Channel
      • 7.3.4.6 Malaysia Insulin Pump Market
        • 7.3.4.6.1 Malaysia Insulin Pump Market by Product
        • 7.3.4.6.2 Malaysia Insulin Pump Market by Disease Indication
        • 7.3.4.6.3 Malaysia Insulin Pump Market by Distribution Channel
      • 7.3.4.7 Rest of Asia Pacific Insulin Pump Market
        • 7.3.4.7.1 Rest of Asia Pacific Insulin Pump Market by Product
        • 7.3.4.7.2 Rest of Asia Pacific Insulin Pump Market by Disease Indication
        • 7.3.4.7.3 Rest of Asia Pacific Insulin Pump Market by Distribution Channel
  • 7.4 LAMEA Insulin Pump Market
    • 7.4.1 LAMEA Insulin Pump Market by Product
      • 7.4.1.1 LAMEA Pumps Market by Country
      • 7.4.1.2 LAMEA Insulin Pump Market by Pumps Type
        • 7.4.1.2.1 LAMEA Tethered Market by Country
        • 7.4.1.2.2 LAMEA Patch Market by Country
        • 7.4.1.2.3 LAMEA Others Market by Country
      • 7.4.1.3 LAMEA Consumables Market by Country
    • 7.4.2 LAMEA Insulin Pump Market by Disease Indication
      • 7.4.2.1 LAMEA Type 1 Diabetes Market by Country
      • 7.4.2.2 LAMEA Type 2 Diabetes Market by Country
    • 7.4.3 LAMEA Insulin Pump Market by Distribution Channel
      • 7.4.3.1 LAMEA Retail & Online Pharmacies Market by Country
      • 7.4.3.2 LAMEA Hospital Pharmacy Market by Country
    • 7.4.4 LAMEA Insulin Pump Market by Country
      • 7.4.4.1 Brazil Insulin Pump Market
        • 7.4.4.1.1 Brazil Insulin Pump Market by Product
        • 7.4.4.1.2 Brazil Insulin Pump Market by Disease Indication
        • 7.4.4.1.3 Brazil Insulin Pump Market by Distribution Channel
      • 7.4.4.2 Argentina Insulin Pump Market
        • 7.4.4.2.1 Argentina Insulin Pump Market by Product
        • 7.4.4.2.2 Argentina Insulin Pump Market by Disease Indication
        • 7.4.4.2.3 Argentina Insulin Pump Market by Distribution Channel
      • 7.4.4.3 UAE Insulin Pump Market
        • 7.4.4.3.1 UAE Insulin Pump Market by Product
        • 7.4.4.3.2 UAE Insulin Pump Market by Disease Indication
        • 7.4.4.3.3 UAE Insulin Pump Market by Distribution Channel
      • 7.4.4.4 Saudi Arabia Insulin Pump Market
        • 7.4.4.4.1 Saudi Arabia Insulin Pump Market by Product
        • 7.4.4.4.2 Saudi Arabia Insulin Pump Market by Disease Indication
        • 7.4.4.4.3 Saudi Arabia Insulin Pump Market by Distribution Channel
      • 7.4.4.5 South Africa Insulin Pump Market
        • 7.4.4.5.1 South Africa Insulin Pump Market by Product
        • 7.4.4.5.2 South Africa Insulin Pump Market by Disease Indication
        • 7.4.4.5.3 South Africa Insulin Pump Market by Distribution Channel
      • 7.4.4.6 Nigeria Insulin Pump Market
        • 7.4.4.6.1 Nigeria Insulin Pump Market by Product
        • 7.4.4.6.2 Nigeria Insulin Pump Market by Disease Indication
        • 7.4.4.6.3 Nigeria Insulin Pump Market by Distribution Channel
      • 7.4.4.7 Rest of LAMEA Insulin Pump Market
        • 7.4.4.7.1 Rest of LAMEA Insulin Pump Market by Product
        • 7.4.4.7.2 Rest of LAMEA Insulin Pump Market by Disease Indication
        • 7.4.4.7.3 Rest of LAMEA Insulin Pump Market by Distribution Channel

Chapter 8. Company Profiles

  • 8.1 Tandem Diabetes Care, Inc
    • 8.1.1 Company Overview
    • 8.1.2 Financial Analysis
    • 8.1.3 Regional Analysis
    • 8.1.4 Research & Development Expenses
    • 8.1.5 Recent strategies and developments:
      • 8.1.5.1 Partnerships, Collaborations, and Agreements:
      • 8.1.5.2 Acquisition and Mergers:
      • 8.1.5.3 Trials and Approvals:
  • 8.2 SOOIL Developments Co., Ltd
    • 8.2.1 Company Overview
    • 8.2.2 Recent strategies and developments:
      • 8.2.2.1 Partnerships, Collaborations, and Agreements:
  • 8.3 Jiangsu Delfu Medical Device Co.,Ltd
    • 8.3.1 Company Overview
  • 8.4 Medtronic PLC
    • 8.4.1 Company overview
    • 8.4.2 Financial Analysis
    • 8.4.3 Segmental and Regional Analysis
    • 8.4.4 Research & Development Expenses
    • 8.4.5 Recent strategies and developments:
      • 8.4.5.1 Product Launches and Product Expansions:
      • 8.4.5.2 Acquisition and Mergers:
      • 8.4.5.3 Trials and Approvals:
    • 8.4.6 SWOT Analysis
  • 8.5 F. Hoffmann-La Roche Ltd.
    • 8.5.1 Company Overview
    • 8.5.2 Financial Analysis
    • 8.5.3 Segmental and Regional Analysis
    • 8.5.4 Research & Development Expense
    • 8.5.5 Recent strategies and developments:
      • 8.5.5.1 Partnerships, Collaborations, and Agreements:
      • 8.5.5.2 Product Launches and Product Expansions:
  • 8.6 Insulet Corporation
    • 8.6.1 Company Overview
    • 8.6.2 Financial Analysis
    • 8.6.3 Regional Analysis
    • 8.6.4 Research & Development Expenses
    • 8.6.5 Recent strategies and developments:
      • 8.6.5.1 Partnerships, Collaborations, and Agreements:
      • 8.6.5.2 Trials and Approvals:
      • 8.6.5.3 Acquisition and Mergers:
      • 8.6.5.4 Geographical Expansions:
  • 8.7 Ypsomed AG
    • 8.7.1 Company Overview
    • 8.7.2 Financial Analysis
    • 8.7.3 Segmental and Regional Analysis
    • 8.7.4 Recent strategies and developments:
      • 8.7.4.1 Partnerships, Collaborations, and Agreements:
  • 8.8 Aetna, Inc. (CVS Pharmacy, Inc.)
    • 8.8.1 Company Overview
    • 8.8.2 Financial Analysis
    • 8.8.3 Segmental Analysis
  • 8.9 Diabeloop SA
    • 8.9.1 Company Overview
    • 8.9.2 Recent strategies and developments:
      • 8.9.2.1 Partnerships, Collaborations, and Agreements:
  • 8.10. APEX Medical Corporation
    • 8.10.1 Company Overview
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제